The Effect of SGLT2 Inhibition on Brain-related Phenotypes and Aging: A Drug Target Mendelian Randomization Study.

Zhihe Chen, Xueyan Wu, Qianqian Yang, Huiling Zhao, Hui Ying, Haoyu Liu, Chaoyue Wang, Ruizhi Zheng, Hong Lin, Shuangyuan Wang, Mian Li, Tiange Wang, Zhiyun Zhao, Min Xu, Yuhong Chen, Yu Xu, Jieli Lu, Guang Ning, Weiqing Wang, Shan Luo, Shiu Lun Au Yeung, Yufang Bi, Jie Zheng

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. · pubmed

Paper

Abstract

An observational study suggested sodium-glucose cotransporter 2 (SGLT2) inhibitors might promote healthy aging. However, whether brain-related phenotypes mediate this association is still a question. We applied Mendelian randomization (MR) to investigate the effect of SGLT2 inhibition on chronological age, biological age, and cognition and explore the mediation effects of brain imaging-derived phenotypes (IDPs).

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the potential effects of SGLT2 inhibitors on brain-related phenotypes and aging through Mendelian randomization. This study is relevant as it explores a drug's impact on aging mechanisms rather than merely addressing age-related diseases or symptoms.

Author of this paper? Send a correction.